收藏切换
Analysis on procurement and affordability of rare disease drugs in National Negotiation Drugs
收藏切换
Junming REN1, 2, Luxinyi XU1, 2, Xue HE1, 2, Jiaqi QIU1, 2, Caixia TENG1, 2, Dan CUI1, 2, *
World Clinical Drug | 2023, 44(6) : 661 - 667
Less
收藏切换
World Clinical Drug | 2023, 44(6): 661-667
• Pharmacy administration •
Analysis on procurement and affordability of rare disease drugs in National Negotiation Drugs
Full
Junming REN1, 2, Luxinyi XU1, 2, Xue HE1, 2, Jiaqi QIU1, 2, Caixia TENG1, 2, Dan CUI1, 2, *
Affiliations
  • 1.School of Public Health, Wuhan University, Wuhan 430071, Hubei Province, China
  • 2.Wuhan University Global Health Institute, Wuhan 430072, Hubei Province, China
Published: 2023-06-10 doi: 10.13683/j.wph.2023.06.025
Outline
收藏切换

In recent years, the number of rare dise ase drugs included in the national medical insurance negotiation list has been increased, and the landing of rare disease drugs in National Negotiation Drugs is the key to evaluate the effect of the policy. Based on the online drug procurement data of medical institutions in Hubei province from January 2018 to December 2022, this article conducted a study on rare disease drugs that had been negotiated four times between 2017 and 2021. Defined daily doses (DDDs), defined daily dose cost and procurement amount were selected to compare before and after the policy, and catastrophic health expenditure indicators were used to evaluate the affordability of rare disease drugs. The analysis revealed that among the 21 negotiated rare disease drugs, 5 drugs were not procured by medical institutions in Hubei province from 2017 - 2021. Compared with 2018, the DDDs and procurement amount decreased in 2019, but the DDDs and amount of negotiated rare disease drugs increased year by year from 2020 to 2022. Before reimbursement by medical insurance, there were 14 and 15 drugs with annual treatment costs exceeding catastrophic health expenditures for urban and rural residents, respectively. After reimbursement by employee medical insurance, there were 7 and 10 drugs with annual treatment costs exceeding catastrophic health expenditures for urban and rural residents, respectively. There were 10 and 13 drugs after reimbursement by residents' medical insurance, respectively. Therefore, it is suggested that the government should take lead improving the multi-party co-payment for rare disease drugs and achieve classified management for the extremely poor population, so as to consolidate the guarantee of people's livelihood.

National Negotiated Drugs  /  rare disease  /  orphan drug  /  affordability
任俊名, 徐陆欣怡, 何雪, 丘佳琪, 滕彩霞, 崔丹. 国家谈判罕见病药品的采购情况及可负担性分析. 世界临床药物, 2023 , 44 (6) : 661 -667 . DOI: 10.13683/j.wph.2023.06.025
Junming REN, Luxinyi XU, Xue HE, Jiaqi QIU, Caixia TENG, Dan CUI. Analysis on procurement and affordability of rare disease drugs in National Negotiation Drugs[J]. World Clinical Drug, 2023 , 44 (6) : 661 -667 . DOI: 10.13683/j.wph.2023.06.025
Year 2023 volume 44 Issue 6
14
2
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2023.06.025
  • Receive Date:2023-02-22
  • Online Date:2026-11-18
  • Published:2023-06-10
Article Data
Affiliations
History
  • Received:2023-02-22
Funding
Affiliations
    1.School of Public Health, Wuhan University, Wuhan 430071, Hubei Province, China
    2.Wuhan University Global Health Institute, Wuhan 430072, Hubei Province, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2023.06.025
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT